Adaptimmune Expands Trial of T-cell Therapy for Synovial Sarcoma and Achieves Clinical Milestones

1 September 2015

Adaptimmune today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

Please click on the link below to download the full Press Release:-

Adaptimmune Expands Trial of T-cell Therapy for Synovial Sarcoma and Achieves Clinical Milestones

 

Adaptimmune to Participate in the Wedbush 2015 Life Sciences Conference

4 August 2015

PHILADELPHIA, Pa. and OXFORD, UK., August 4, 2015 – Adaptimmune Therapeutics plc (Nasdaq: ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company focused on the use of

T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Chief Financial Officer of Adaptimmune, will present at the Wedbush 2015 Life Sciences Conference at 9:45 AM ET (2:45 PM BST) on Tuesday, August 11, 2015. The conference is being held in New York City.

Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 14 days following the conference.

Please click on the link below to download the full Press Release:-

Adaptimmune to Participate in the Wedbush 2015 Life Sciences Conference

Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence, Clinical Activity and Tolerability in Clinical Study in Multiple Myeloma Patients

20 July 2015

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine. The paper entitled NY-ESO-1 Specific TCR Engineered T-cells Mediate Sustained Antigen-specific Antitumor Effects in Myeloma by Drs. Aaron P. Rapoport, Edward Stadtmauer and Gwendolyn Binder-Scholl et al. describes the persistence and tumor trafficking, antitumor effect and safety profile of Adaptimmune’s NY-ESO TCR therapeutic (ADAP NY-ESO TCR) in 20 patients with advanced multiple myeloma.

Please click on the link below to download the full Press Release:-
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence, Clinical Activity and Tolerability in Clinical Study in Multiple Myeloma Patients

Adaptimmune Announces FDA Acceptance of Investigational New Drug (IND) Application for MAGE-A10 T in Patients with Non-small Cell Lung Cancer

2 July 2015

Adaptimmune, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors (TCRs) specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), and that the IND is now active.

Please click on the link below to download the full Press Release:-

Adaptimmune Announces FDA Acceptance of Investigational New Drug (IND) Application for MAGE-A10 T in Patients with Non-small Cell Lung Cancer

 

Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting

30 May 2015

Adaptimmune today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers. Eighty-two (82) patients have been treated to date with NY-ESO-T; 44 under Adaptimmune’s IND, and 38 under a National Cancer Institute IND (Robbins et al., CCR, 2014). The data from Adaptimmune’s clinical studies in synovial sarcoma, multiple myeloma and ovarian cancer were presented at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting.

Please click on the link below to download the full Press Release:-

Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting

 

 

Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting

21 May 2015

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting. These data pertain to clinical results from myeloma, synovial sarcoma and ovarian cancer patients who have been dosed with affinity-enhanced, TCR engineered T-cells targeting NY-ESO-1. ASCO brings together more than 30,000 physicians from around the world to discuss state-of-the-art advances and persisting challenges in the field of oncology. The meeting will take place at the McCormick Place exhibition center in Chicago, Illinois on May 29 through June 2, 2015.

Please click on the link below to download the full Press Release:-

Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting